Method for producing high-purity compound and method for purifying high-purity compound
By using alkali metal iodide and acetonitrile solvent to synthesize AFDX0250 under alkaline conditions, combined with extraction and crystallization treatment, the problems of low manufacturing yield and difficulty in purification of AFDX0250 are solved, and high yield and high purity are achieved AFDX0250 is produced, reducing drug development costs and enhancing safety.
Patent Information
- Application Number
- CN202380031604.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-29
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the manufacturing method of AFDX0250 has low yields and is difficult to purify in high purity, resulting in high drug development costs and possible side effects.
Under basic conditions, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyridino[2,3-b][1,4]benzodiazepine-6-one was used with (R)-2-(diethylamino)methylpiperidine reaction, and the acetonitrile solvent and alkali metal iodide as a medium combined with multiple extraction and crystallization treatments to achieve high yield and high purity AFDX0250 preparation with high yield and high purity have to.
Improve the yield and purity of AFDX0250, inhibiting 11-(2-chloroacetyl)-5,11-dihydro-6H-pyridino[2,3-b][1,4]benzodiazepine- The impurity content of 6-ketone reduces the cost of drug development and enhances safety.
Smart Images

Figure CN118946564A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The present invention relates to a method for producing and purifying 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. -6-ketone (hereinafter, sometimes referred to as "Compound 1") and other impurities. Background Art
[0002] AFDX0250 is (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Keto has the structure shown below and is known to be useful in the treatment of ophthalmic diseases such as glaucoma, ocular hypertension and myopia (Patent Documents 1 and 2).
[0003] [Chemical formula 1]
[0004]
[0005] Non-patent document 1 and patent document 3 disclose methods for producing AFDX0250. Non-patent document 1 discloses that 11-(chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine is reacted in acetonitrile in the presence of sodium carbonate according to a general procedure. -6-ketone is reacted with (-)-2-[(diethylamino)methyl]piperidine to produce AFDX0250. In addition, Patent Document 3 also discloses a method in which 11-(chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine is reacted in acetonitrile in the presence of sodium carbonate to produce AFDX0250. The -6-ketone was reacted with (-)-2-[(diethylamino)methyl]piperidine to produce AFDX0250, but the yield was low at 59%.
[0006] In order to make AFDX0250 into a pharmaceutical product and sell it, it is important to produce AFDX0250 with a high yield and to purify it efficiently. In addition, in order to prevent undesired effects, it is important to remove impurities from the crude product and produce it with high purity.
[0007] Prior art literature
[0008] Patent Literature
[0009] Patent Document 1: International Publication No. 93 / 18772
[0010] Patent Document 2: International Publication No. 2022 / 030489
[0011] Patent Document 3: Japanese Patent Application Laid-Open No. 60-215683
[0012] Non-patent literature
[0013] Non-patent document 1: Wolfnard W. Engel et al., J. Med. Chem., 1989, 32(8), 1718-1724 Summary of the invention
[0014] Problems to be solved by the invention
[0015] In order to meet the approval criteria for quality and purity, drugs require high purity. For example, due to the generation of impurities during the manufacture and / or storage of drugs, problems such as reduced therapeutic effects and the occurrence of unwanted side effects sometimes occur. In addition, if the yield of a compound useful as an active ingredient of a drug is low, it is difficult to synthesize or industrially produce the compound in large quantities, and there is also a problem of high cost in the development of drugs. As mentioned above, the manufacturing method of AFDX0250 is disclosed in Non-Patent Document 1 and Patent Document 3, but the yield of the manufactured AFDX0250 is low. Therefore, in order to use it as a drug, there is room for improving the previous manufacturing method of AFDX0250.
[0016] Furthermore, the inventors of the present application discovered that, during the development stage of a pharmaceutical composition containing AFDX0250 or a salt thereof, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine contained in the produced AFDX0250 -6-Keto is positive in the Ames test, and it is considered desirable to remove this compound from the viewpoint of the occurrence of side effects.
[0017] Therefore, the object of the present invention is to provide a novel 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-free The present invention also aims to provide a high-yield and high-purity AFDX0250 or a salt thereof that is substantially free of impurities, and a highly safe pharmaceutical composition containing high-purity AFDX0250.
[0018] Means for solving problems
[0019] The inventors of the present application have conducted intensive research to solve the above-mentioned problems and have found that 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The inventors of the present application have found that the specific conditions of the method for producing AFDX0250 or a salt thereof in high yield and high purity by using 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in a mixture containing 1 g of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine In an organic solvent of acetonitrile in an amount of 15 to 50 mL for 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine, in the presence of an alkali metal iodide, under alkaline conditions, The present invention has been completed by reacting (R)-2-(diethylamino)methylpiperidine or its salt with (R)-2-(diethylamino)methylpiperidine or its salt to produce AFDX0250 or its salt in high yield and high purity, and further, by appropriately adjusting the solvent and temperature, the obtained crude product of AFDX0250 can be crystallized with high purity.
[0020] Specifically, the present invention provides the following aspects.
[0021] [Item 1] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt production method, comprising the step of: 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine a step of reacting (R)-2-(diethylamino)methylpiperidine or a salt thereof with (R)-2-(diethylamino)methylpiperidine or a salt thereof in an organic solvent in the presence of an alkali metal iodide under alkaline conditions,
[0022] The organic solvent contains 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For -6-ketone or its salt, 15 to 50 mL of acetonitrile.
[0023] [Item 2] The production method according to Item 1, wherein the organic solvent is 1 g of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For -6-ketone or its salt, 15 to 50 mL of acetonitrile.
[0024] [Item 3] The production method according to Item 1 or Item 2, comprising the steps of adding water and an acid to the reaction mixture to adjust the pH, followed by extraction with an organic solvent.
[0025] [Item 4] The production method according to Item 3, wherein the extraction with an organic solvent is carried out two or more times.
[0026] [Item 5] The production method according to Item 3 or Item 4, wherein the organic solvent is ethyl acetate.
[0027] [Item 6] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt production method, comprising the step of: 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of reacting -6-ketone or a salt thereof with (R)-2-(diethylamino)methylpiperidine or a salt thereof in an organic solvent under alkaline conditions.
[0028] [Item 7] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of crystallizing the -6-ketone or its salt in a mixed solution of 1-propanol and water.
[0029] [Item 8] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of treating -6-ketone or its salt with activated carbon in an alcohol solvent.
[0030] [Item 9] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of recrystallizing -6-ketone or a salt thereof in a mixed solution of an alcoholic solvent and a ketone solvent.
[0031] [Item 10] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, the purity of which is 95% or more.
[0032] [Item 11] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, wherein the content of impurities is less than 5%.
[0033] [Item 12] A pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, derived from (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of impurities in (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of α-6-ketone or its salt is less than 5%.
[0034] [Item 13] The pharmaceutical composition according to Item 12, wherein the impurity content is less than 1%.
[0035] [Item 14] A pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, and substantially free of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof.
[0036] [Item 15] The pharmaceutical composition according to Item 14, wherein 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of -6-ketone or its salt relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For 1-6-ketone or its salt, the concentration is less than 1000 ppm.
[0037] [Item 16] The pharmaceutical composition according to Item 14 or Item 15, which is substantially free of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof.
[0038] [Item 17] The pharmaceutical composition according to Item 16, wherein 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of -6-ketone or its salt is less than 1000 ppm.
[0039] It should be noted that two or more of the above-mentioned structures of [Item 1] to [Item 17] may be arbitrarily selected and combined.
[0040] Furthermore, the present invention provides the following aspects.
[0041] [Item 18] The pharmaceutical composition according to any one of Items 12 to 17, which is an eye drop.
[0042] [Item 19] The pharmaceutical composition according to any one of Items 12 to 18, which is used for treating glaucoma, ocular hypertension or myopia.
[0043] Effects of the Invention
[0044] According to the production method and purification method of the present invention, compared with the known method, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can be produced with high yield and high purity. -6-ketone or its salt. In addition, it can inhibit 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone and other impurities.
[0045] In addition, the present invention can provide high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt, and (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine containing high purity A pharmaceutical composition of -6-ketone or a salt thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] [ Figure 1 ] shows the properties of AFDX0250 samples (powder and DMSO solution) containing each solvent (ethanol (EtOH), 1-propanol (1-PrOH) and N-methylpyrrolidone (NMP)) before and after activated carbon treatment using Egret A (0.05w / w, 0.10w / w and 0.15w / w) and Egret P (0.10w / w and 0.15w / w). It should be noted that, with respect to the sample containing NMP as a solvent, no sample using Egret A (0.15w / w) and Egret P (0.10w / w and 0.15w / w) was prepared.
[0047] [ Figure 2 ] shows the properties of the dried products and DMSO solutions obtained by using ethanol as an alcohol solvent and acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK) or n-heptane as a poor solvent, and for their combinations, carrying out a recrystallization process with respective total solvent amounts of 10 v / w (ratio 1:3) and 20 v / w (ratio 1:1), as well as the properties of the dried products and DMSO solutions before purification.
[0048] [ Figure 3] shows the properties of the dried products and DMSO solutions obtained by using 1-propanol as an alcohol solvent and acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK) or n-heptane as a poor solvent, and for their combinations, carrying out a recrystallization process with respective total solvent amounts of 10 v / w (ratio 1:3) and 20 v / w (ratio 1:1), as well as the dried products and DMSO solutions before purification. DETAILED DESCRIPTION
[0049] Hereinafter, the present invention will be described in detail.
[0050] The present invention provides (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt production method, comprising the step of making 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of reacting 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in an organic solvent (preferably acetonitrile) in the presence of an alkali metal iodide under alkaline conditions. -6-ketone or a salt thereof, (R)-2-(diethylamino)methylpiperidine or a salt thereof, an organic solvent containing acetonitrile (preferably acetonitrile), an alkali metal iodide and a base are mixed, heated and stirred, and then concentrated to obtain a reaction mixture.
[0051] 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine as a raw material in this step As for (R)-6-ketone or a salt thereof and (R)-2-(diethylamino)methylpiperidine or a salt thereof, commercially available products may be used, or those produced by a known method may be used.
[0052] The "organic solvent" in this step includes acetonitrile, preferably only acetonitrile. The amount of acetonitrile added is 15 v / w to 50 v / w, preferably 15 v / w to 40 v / w, more preferably 15 v / w to 30 v / w, further preferably 18 v / w to 25 v / w, and most preferably 20 v / w.
[0053] It should be noted that the amount of acetonitrile added "v / w" refers to the amount of acetonitrile added relative to 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of acetonitrile relative to the mass (1 g) of -6-ketone. The same shall apply unless otherwise specified.
[0054] As the "alkali metal iodide" in this step, for example, sodium iodide, potassium iodide, calcium iodide, lithium iodide, etc. can be mentioned, preferably sodium iodide. In addition, the alkali metal iodide can be used alone, or two or more kinds can be used in any combination and ratio. The amount of the alkali metal iodide added is, for example, 0.01 to 2 equivalents, preferably 0.05 to 1.5 equivalents, more preferably 0.1 to 1 equivalents, further preferably 0.15 to 0.5 equivalents, particularly preferably 0.2 to 0.4 equivalents, and most preferably 0.25 equivalents.
[0055] It should be noted that the "equivalent amount" of the amount of alkali metal iodide added refers to the amount of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The amount of substance (mol) of the alkali metal iodide relative to the amount of substance (1 mol) of -6-ketone. The same shall apply hereinafter unless otherwise specified.
[0056] As the "alkaline conditions" in this step, for example, alkaline conditions based on lithium carbonate, sodium carbonate, cesium carbonate, potassium carbonate, lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, lithium hydride, sodium hydride, potassium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, alkyl lithium (for example, n-butyl lithium, sec-butyl lithium, tert-butyl lithium, n-hexyl lithium), lithium amide (for example, diisopropyl lithium amide, lithium hexamethyldisilazide), sodium methoxide, sodium ethoxide, or tertiary amine (for example, trimethylamine, triethylamine, tripropylamine, triisopropylamine, diisopropylethylamine) and the like can be cited, preferably alkaline conditions based on sodium bicarbonate, triethylamine or diisopropylethylamine. The base can be used alone or in any combination and ratio. Two or more bases can be used. The amount of the base added is, for example, 1 to 20 equivalents, preferably 1.5 to 15 equivalents, more preferably 2 to 10 equivalents, further preferably 2.5 to 8 equivalents, particularly preferably 3 to 5 equivalents, and most preferably 3.15 equivalents.
[0057] It should be noted that the "equivalent" amount of the added base refers to the amount of the base added relative to 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The amount of the substance (mole) of the base relative to the amount of the substance (1 mol) of the -6-ketone. The same shall apply hereinafter unless otherwise specified.
[0058] The reaction temperature in this step is, for example, 40 to 100°C, preferably 50 to 90°C, more preferably 60 to 80°C, further preferably 65 to 78°C, and most preferably 70 to 75°C.
[0059] The reaction time in this step varies depending on conditions such as the reaction temperature and is therefore not particularly limited, but is appropriately selected between 1 and 48 hours, preferably 3 to 36 hours, more preferably 6 to 30 hours, further preferably 12 to 27 hours, particularly preferably 18 to 24 hours, and most preferably 20 hours.
[0060] The production method of the present invention comprises the following steps: concentrating the reaction mixture obtained in the above step to, for example, 3 to 12 v / w, preferably 4 to 10 v / w, more preferably 5 to 8 v / w, and most preferably 6 to 7 v / w, and adding water and an acid to adjust the reaction mixture to a temperature capable of producing (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt is dissolved in water, followed by extraction with an organic solvent. In this step, water is added to the reaction mixture, followed by addition of an acid to adjust the pH to an acidic pH, for example, 3.0 or less, more preferably 2.0 or less, and most preferably 1.0 or less, and extraction with an organic solvent is performed once or more, preferably twice or more, more preferably three or more times, and most preferably four or more times.
[0061] It should be noted that the "v / w" content of the reaction mixture refers to the amount of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of the reaction mixture was expressed based on the mass (1 g) of -6-ketone.
[0062] The amount of water added in this step is, for example, 3 to 50 v / w, preferably 5 to 30 v / w, more preferably 7 to 20 v / w, further preferably 8 to 15 v / w, and most preferably 10 v / w.
[0063] It should be noted that the amount of water added "v / w" refers to the amount of water added relative to 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of water relative to the mass (1 g) of -6-ketone. The same shall apply unless otherwise specified.
[0064] The acid used in this step is any acid that can be adjusted to react with (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The acid may be any acid with a pH at which the (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. The amount of -6-ketone or a salt thereof is not particularly limited as long as it is dissolved in water at a pH.
[0065] As the organic solvent in this step, for example, chloroform, dichloromethane, ether, tetrahydrofuran (THF), ethyl acetate, hexane, toluene, etc. can be mentioned, preferably ethyl acetate. The amount of the organic solvent added is, for example, 5 v / w to 50 v / w, preferably 10 v / w to 40 v / w, and most preferably 10 v / w.
[0066] It should be noted that the amount of organic solvent added "v / w" refers to the amount of organic solvent added relative to 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of the organic solvent relative to the mass (1 g) of -6-ketone.
[0067] The temperature when adding water and the acid in this step is, for example, -10 to 30°C, preferably -5 to 20°C, more preferably 0 to 15°C, and most preferably 0 to 10°C.
[0068] The production method of the present invention includes a step of adding a solvent to the organic layer obtained in the above step to perform crystallization. In this step, a solvent is added to the organic layer, and then a base is added to adjust the pH to alkaline, preferably 8 to 12, more preferably 9 to 11, and stirred, thereby (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The precipitated crystals are separated by filtration, washed, and dried, thereby obtaining high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. -6-ketone or a salt thereof.
[0069] As the solvent in this step, for example, water, a mixture of methanol and water, a mixture of ethanol and water, a mixture of acetone and water, a mixture of methyl ethyl ketone and water, a mixture of acetonitrile and water, a mixture of N,N-dimethylformamide and water, etc. can be cited, preferably a mixture of acetonitrile and water. When a mixture of acetonitrile and water is used as the solvent, the volume ratio of acetonitrile to water is, for example, 1:1 to 1:10, preferably 1:2 to 1:6, and most preferably 1:3 to 1:5. The amount of the solvent added is, for example, 5 to 20 v / w, preferably 8 to 16 v / w, and more preferably 10 to 14 v / w.
[0070] It should be noted that the amount of solvent added "v / w" refers to the amount of solvent added relative to 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of the solvent relative to the mass (1 g) of -6-ketone.
[0071] The alkali in this step is not particularly limited as long as it can adjust the pH to alkaline, preferably 8 to 12, more preferably 9 to 11. For example, lithium carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, etc. can be mentioned, preferably potassium hydroxide. The amount of the alkali added is not particularly limited as long as it can adjust the pH to alkaline, preferably 8 to 12, more preferably 9 to 11.
[0072] The temperature during stirring in this step is, for example, -10 to 20°C, preferably -5 to 15°C, and most preferably 0 to 10°C.
[0073] The stirring time in this step varies depending on reaction conditions such as temperature and is not particularly limited, but is appropriately selected from 1 to 24 hours, preferably 1 to 12 hours, more preferably 2 to 8 hours, and most preferably 3 to 5 hours.
[0074] The drying temperature in this step is not particularly limited as long as it is a range in which adhering moisture or solution can be removed, and is, for example, 30 to 100°C, preferably about 50°C.
[0075] In the production method of the present invention, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can be removed. -6-ketone or a salt thereof.
[0076] The present invention also provides (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt production method, comprising the step of making 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of reacting -6-ketone or a salt thereof with (R)-2-(diethylamino)methylpiperidine or a salt thereof in an organic solvent under alkaline conditions.
[0077] As the "organic solvent" in the present production method, for example, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), ethyl acetate, etc. The amount of the organic solvent added is, for example, 3 v / w to 50 v / w, preferably 5 v / w to 30 v / w, more preferably 7 v / w to 20 v / w, further preferably 8 v / w to 15 v / w, and most preferably 10 v / w.
[0078] It should be noted that the amount of organic solvent added "v / w" refers to the amount of organic solvent added relative to 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of the organic solvent relative to the mass (1 g) of -6-ketone.
[0079] As the "alkaline conditions" in the present production method, for example, alkaline conditions based on sodium carbonate, cesium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium tert-butoxide, potassium tert-butoxide, alkyl lithium (for example, n-butyl lithium, sec-butyl lithium, tert-butyl lithium, n-hexyl lithium), lithium amide (for example, diisopropyl lithium amide, hexamethyldisilazane lithium salt), sodium methoxide, or tertiary amine (for example, trimethylamine, triethylamine, triisopropylamine, diisopropylethylamine) and the like can be cited, preferably alkaline conditions based on sodium bicarbonate, triethylamine or diisopropylethylamine. The base can be used alone or in any combination and ratio. The amount of the base added is 1 to 20 equivalents, preferably 1.5 to 15 equivalents, more preferably 2 to 10 equivalents, further preferably 2.5 to 8 equivalents, particularly preferably 3 to 5 equivalents, and most preferably 3.15 equivalents.
[0080] It should be noted that the "equivalent" amount of the added base refers to the amount of 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. The amount of base substance (mole) is based on the amount of -6-ketone substance (1 mol).
[0081] The reaction temperature in the present production method is, for example, 40 to 100°C, preferably 50 to 90°C, more preferably 60 to 80°C, further preferably 65 to 78°C, and most preferably 70 to 75°C.
[0082] The reaction time in the present production method varies depending on conditions such as the reaction temperature and is therefore not particularly limited, and is appropriately selected, for example, between 1 and 48 hours, preferably between 3 and 36 hours, more preferably between 6 and 30 hours, further preferably between 12 and 27 hours, particularly preferably between 18 and 24 hours, and most preferably between 20 hours.
[0083] The present invention provides a high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising the steps of: treating a crude product (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine obtained by the production method of the present invention with water; -6-ketone or its salt is crystallized in a mixture of 1-propanol and water. In the present purification method, the crude product (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine is crystallized in a mixture of 1-propanol and water. -6-ketone or its salt is mixed with 1-propanol, heated and stirred, cooled, water is added and stirred, and then further cooled, thereby obtaining (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The precipitated crystals are aged, separated by filtration, washed, and dried, thereby obtaining high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. -6-ketone or a salt thereof.
[0084] The amount of 1-propanol added in the present purification method is, for example, 1 to 10 v / w, preferably 2 to 8 v / w, more preferably 3 to 15 v / w, and most preferably 4 v / w.
[0085] The amount of water added in the present purification method is, for example, 1 to 15 v / w, preferably 2 to 10 v / w, more preferably 4 to 8 v / w, and most preferably 6 v / w.
[0086] The "v / w" of the added amounts of 1-propanol and water refers to the amount of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. The volume (mL) of 1-propanol and water for the mass (1 g) of -6-ketone or its salt.
[0087] The temperature of each step in the present purification method can be adjusted appropriately. For example, when stirring in 1-propanol, it is heated to 80 to 100°C, preferably 85 to 95°C. Then it is cooled to 40 to 60°C, preferably 45 to 55°C, and water is added and stirred. It can be further cooled to -5 to 10°C, preferably 0 to 5°C, and ripened. The drying temperature can be any as long as it is within the range that the attached water or solution can be removed, for example, below 80°C, preferably about 50°C.
[0088] The stirring time in 1-propanol in the present purification method is not particularly limited, and is appropriately selected, for example, between 1 and 5 hours, preferably between 2 and 4 hours, and most preferably between 3 hours. The stirring time after adding water is appropriately selected, for example, between 10 minutes and 5 hours, preferably between 20 minutes and 4 hours, and most preferably between 30 minutes and 3 hours.
[0089] In the present purification method, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can be purified by -6-ketone or its salt specific impurities are removed.
[0090] The present invention also provides a high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising the step of treating a crude product (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine obtained by the production method of the present invention with water. The purification method comprises: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt is treated with activated carbon in an alcohol solvent; and / or a recrystallization process is performed in a mixed solution of an alcohol solvent and a ketone solvent. Specifically, in the activated carbon treatment process, the following process is included: AFDX0250 and activated carbon are mixed with an alcohol solvent as a good solvent, heated and stirred, carbon filtered and concentrated. In the recrystallization process, the following process is included: a ketone solvent as a poor solvent is added to the concentrated mixture, heated and stirred, cooled, thereby crystallizing AFDX0250, ripening the precipitated crystals, separating by filtration, washing and drying, thereby obtaining high-purity AFDX0250. In addition, in order to obtain AFDX0250 with higher purity, the same operation except for the addition of activated carbon and carbon filtration can be repeated multiple times. In addition, it is also possible to perform only the recrystallization process without performing the activated carbon treatment process.
[0091] Examples of the "alcohol solvent" in the present purification method include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and 2-butanol, preferably ethanol and 1-propanol. The amount of the alcohol solvent added is, for example, 5 to 50 v / w, preferably 10 to 40 v / w, more preferably 15 to 30 v / w, and most preferably 20 v / w.
[0092] It should be noted that the amount of alcohol solvent added "v / w" refers to the amount of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of the alcohol solvent relative to the mass (1 g) of -6-ketone or its salt.
[0093] Examples of the "activated carbon" in the present purification method include Shirasagi A and Shirasagi P, preferably Shirasagi A. The amount of activated carbon added is, for example, 0.01 to 0.3 w / w, preferably 0.03 to 0.2 w / w, and most preferably 0.05 to 0.15 w / w.
[0094] It should be noted that the "w / w" of the amount of activated carbon added refers to the amount of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The mass (g) of activated carbon is expressed as the mass (1 g) of -6-ketone or its salt.
[0095] In the present purification method, after the activated carbon filtration, the mixed solution is concentrated until the alcohol solvent becomes, for example, 0.5 to 3 v / w, preferably 1 to 3 v / w, and more preferably 2 to 2.5 v / w. In the middle of or after the concentration, a ketone solvent is added in an amount of, for example, 3 to 15 v / w, preferably 5 to 10 v / w, and more preferably 7 to 8 v / w, thereby forming a mixed solution of an alcohol solvent and a ketone solvent. In the case where only the recrystallization step is performed without performing the activated carbon treatment step, the solvent for recrystallization is also a mixed solution of an alcohol solvent and a ketone solvent, and the amount of the alcohol solvent added is, for example, 0.5 to 3 v / w, preferably 1 to 3 v / w, and more preferably 2 to 2.5 v / w, and the amount of the ketone solvent added is, for example, 3 to 15 v / w, preferably 5 to 10 v / w, and more preferably 7 to 8 v / w.
[0096] It should be noted that the content of the alcohol solvent in the mixed solution and the amount of the alcohol solvent and the ketone solvent added are expressed in terms of "v / w" relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The volume (mL) of the mixed solution, the alcohol solvent and the ketone solvent based on the mass (1 g) of -6-ketone or its salt.
[0097] Examples of the “ketone solvent” in the present purification method include acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), and diethyl ketone, and acetone, MEK, and MIBK are preferred.
[0098] The temperature of each step in the present purification method can be adjusted appropriately. For example, the activated carbon treatment step can be implemented by heating and stirring at a temperature of, for example, 50 to 90°C, preferably 60 to 80°C, and more preferably 65 to 75°C. The recrystallization step can be implemented in the following manner: after crystallization at a temperature of, for example, 50 to 80°C, preferably 60 to 70°C, and more preferably 63 to 67°C, stirring is performed as needed, and cooling to, for example, -10 to 15°C, preferably -5°C to 10°C, and more preferably 0 to 5°C. In addition, the aging in the recrystallization step can be implemented at, for example, -10 to 15°C, preferably -5°C to 10°C, and more preferably 0 to 5°C.
[0099] The time for heating and stirring in the activated carbon treatment step in the present purification method varies depending on the conditions and is therefore not particularly limited, and is appropriately selected, for example, between 30 minutes and 24 hours, preferably between 40 minutes and 12 hours, more preferably between 50 minutes and 6 hours, further preferably between 1 hour and 3 hours, and most preferably between 1 hour. The aging in the recrystallization step is, for example, between 6 and 48 hours, preferably between 12 and 36 hours, and most preferably between 24 hours.
[0100] In the present invention, the starting material, intermediate, and / or manufactured compound (AFDX0250) may be in the form of a salt. The manufacturing method of the present invention also includes a manufacturing method in the form of a salt thereof. The salts of these compounds are not particularly limited as long as they are pharmaceutically acceptable salts. Examples of their salts include: salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, and phosphoric acid; salts with organic acids such as acetic acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptonic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, alanine, lactic acid, hippuric acid, 1,2-ethanedisulfonic acid, isethionic acid, lactobionic acid, oleic acid, gallic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl sulfuric acid, methyl sulfate, naphthalenesulfonic acid, and sulfosalicylic acid; salts with metals such as sodium, potassium, calcium, and magnesium; salts with inorganic compounds such as ammonia; and salts with organic amines such as triethylamine and guanidine; and the like.
[0101] In the present invention, the starting material, intermediate, and / or manufactured compound (AFDX0250) or a salt thereof may be in the form of a hydrate or a solvate.
[0102] The production method and purification method of the present invention can obtain high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The purity of -6-ketone or its salt is usually 95% or more, preferably 97% or more, more preferably 99% or more, and most preferably 99.5% or more.
[0103] The production method and purification method of the present invention can produce (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine. The content of impurities in -6-ketone or its salt is removed to, for example, less than 5%, preferably less than 3%, more preferably 1%, and most preferably 0.5%. Here, in the present invention, "impurities" refer to impurities derived from (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt impurity refers to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine contaminated during the production or purification of 6-ketone or its salt -6-keto, 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-keto, 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Keto and other substances.
[0104] In the present invention, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The purity and impurity content of -6-ketone or its salt can be determined by: quantitative determination using the area percentage method with the peak area ratio in liquid chromatography (HPLC), which is a method well known in the field of analytical chemistry; and quantitative determination using liquid chromatography mass spectrometry (LC / MS).
[0105] (1) (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyridine Benz[2,3-b][1,4]benzodiazepine Determination of the content of -6-ketone (AFDX0250) or its salt
[0106] The content of AFDX0250 or a salt thereof can be measured, for example, by the following method.
[0107] <Mobile phase and solvent>
[0108] The following mobile phases and solvents were used.
[0109] Mobile phase A: 0.1 mol / L sodium perchlorate solution (pH 3.0)
[0110] 14.0 g of sodium perchlorate monohydrate was dissolved in 1000 mL of water, and 1 mol / L hydrochloric acid test solution was added to adjust the pH to 3.0.
[0111] Mobile phase B: acetonitrile
[0112] Dissolving solution A: mobile phase A: mobile phase B (1:1) (v / v)
[0113] <Preparation of AFDX0250 standard solution>
[0114] Accurately weigh about 10 mg of AFDX0250, add dissolving solution A, and accurately make up to 100 mL.
[0115] <Preparation of sample solution>
[0116] The sample solution was prepared by the following method.
[0117] Sample solution A: 100 to 200 mg of a reaction suspension containing AFDX0250 (the reaction solution obtained in step 1 of Example 1 described below) was taken and dissolved in 10 mL of a dissolving solution A.
[0118] Sample solution B: Take about 200 μL of the reaction suspension containing AFDX0250 (the reaction solution obtained in step 1 of Example 1 below), filter under reduced pressure using a Kiriyama funnel (S-40), Kiriyama filter paper (No. 3) and a suction bottle, and dissolve about 10 mg of the filtrate in 10 mL of dissolving solution A.
[0119] Sample solution C: About 10 mg of the obtained solid (AFDX0250 obtained in step 3 of Example 1 described below) was accurately weighed, and dissolved in the dissolving solution A, and the volume was accurately fixed to 100 mL.
[0120] Sample solution D: About 100 μL of the aqueous layer (the aqueous layer obtained in step 2 of Example 1 described below) was accurately weighed, and the dissolving solution A was added to accurately adjust the volume to 10 mL.
[0121] <Measurement method>
[0122] Each sample solution was measured by liquid chromatography under the following method and conditions. Furthermore, the content (%) of AFDX0250 was calculated by the following calculation formula.
[0123] (Liquid Chromatography (UHPLC) Test Conditions)
[0124] Detector: UV spectrophotometer (measurement wavelength 210nm)
[0125] ·Chromatographic column: AQUITY UPLC HSS T3 (inner diameter 2.1 mm, length 100 mm, particle size 1.8 μm; Waters)
[0126] Ghost Trap: Ghost Trap DS-HP (P / N: 228-59931-91) (Shimadzu Corporation) or a column with equivalent performance quality (In order to remove impurities in the mobile phase, the ghost trap is connected to the mobile phase mixer.)
[0127] Column temperature: around 40°C
[0128] Sample cooler temperature: around 10°C
[0129] Mobile phase A: 0.1 mol / L sodium perchlorate solution (pH 3.0)
[0130] Mobile phase B: acetonitrile
[0131] · Mobile phase delivery: The mixing ratio of mobile phase A and mobile phase B was controlled as shown in Table 1 to obtain a concentration gradient.
[0132] [Table 1]
[0133] Time since sample injection (minutes) Mobile phase A (%) Mobile phase B (%) 0.00-16.00 95→40 5→60 1 6.00-20.00 40 60 20.00-20.10 40→95 60→5 20.10-24.00 95 5
[0134] Flow rate: 0.5mL / min
[0135] Injection volume: 2μL
[0136] Area measurement range: from the peak of the solvent to 20 minutes after injection
[0137] (Calculation formula)
[0138] Sample solutions A to C:
[0139] AFDX0250 content (%) = 100 x AAp / ATp
[0140] AAp: AFDX0250 peak area obtained from the sample solution
[0141] ATp: Total peak area obtained from the sample solution
[0142] Sample solution D:
[0143] AFDX0250 content (%) = 100 × MS × AT × 10 / (MT × AS × 100)
[0144] MS: Collection amount of AFDX0250 (mg)
[0145] MT: The amount of sample solution collected (mg)
[0146] AS: AFDX0250 peak area obtained from standard solution
[0147] AT: AFDX0250 peak area obtained from the sample solution
[0148] (2) 11-(2-Chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Keto (Compound 1) content determination method
[0149] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of Compound 1 contained in -6-ketone or a salt thereof can be measured, for example, by the following method.
[0150] <Mobile phase and solvent>
[0151] The following mobile phases and solvents were used.
[0152] Mobile phase C: 10 mM ammonium acetate solution
[0153] 0.77 g of ammonium acetate was dissolved in 1000 mL of water.
[0154] Mobile phase B: acetonitrile
[0155] Dissolving liquid B: mobile phase C: mobile phase B (7:3) (v / v)
[0156] <Preparation of standard solution of compound 1>
[0157] Compound 1 standard stock solution: Accurately weigh about 20 mg of compound 1, add dissolving solution B and dissolve it, and accurately adjust the volume to 100 mL. If it is difficult to dissolve, use ultrasound for about 1 minute to dissolve it. Accurately weigh 2 mL of this liquid, add dissolving solution B, and accurately adjust the volume to 20 mL. Accurately weigh 1 mL of this liquid, add dissolving solution B, and accurately adjust the volume to 20 mL.
[0158] Compound 1 standard solution 1: Accurately weigh 4 mL of the standard stock solution, add dissolving solution B, and accurately make up to 20 mL.
[0159] Compound 1 Standard Solution 2: Accurately weigh 2 mL of Standard Solution 1, add Dissolving Solution B, and accurately make up to 10 mL.
[0160] Compound 1 standard solution 3: Accurately weigh 2 mL of standard solution 2, add dissolving solution B, and accurately make up to 20 mL.
[0161] <Preparation of sample solution>
[0162] The sample solution was prepared by the following method.
[0163] Sample solution E (when the measurement object is the water layer): Calculate the AFDX0250 content (%) of the water layer obtained according to the measurement method (1) above. Accurately weigh the water layer so that the AFDX0250 contained is about 100 mg, add the dissolving solution B, and accurately adjust the volume to 25 mL.
[0164] Sample solution F (when the measurement object is a crystal): Accurately weigh about 100 mg of AFDX0250, add 5 mL of solution B and 0.2 mL of dilute hydrochloric acid to dissolve it, and add solution B to accurately adjust the volume to 25 mL (AFDX0250 concentration: about 4 mg / mL). If it is difficult to dissolve, use ultrasound to dissolve it.
[0165] <Measurement method>
[0166] Each sample solution was measured by liquid chromatography-mass spectrometry under the following conditions in the order and number of times shown in Table 3. Furthermore, a calibration curve was prepared based on the concentration (μg / mL) and peak area of the standard solution (using a total of 6 results of standard solutions 1 to 3), and the concentration (μg / mL) of compound 1 in the sample solution and the content (ppm) of compound 1 in AFDX0250 were calculated using the following calculation formula.
[0167] (Experimental conditions of liquid chromatography mass spectrometry (LC / MS))
[0168] Detector: Mass spectrometer
[0169] Monitored ions: m / z 288 (ESI, Positive)
[0170] ·Chromatographic column: X Bridge C18 (inner diameter 2.1 mm, length 150 mm, particle size 3.5 μm; Waters)
[0171] Column temperature: around 40°C
[0172] Sample cooler temperature: Let the temperature be what it is
[0173] Mobile phase C: 10 mM ammonium acetate solution
[0174] Mobile phase B: acetonitrile
[0175] · Mobile phase delivery: The mixing ratio of mobile phase C and mobile phase B was controlled as shown in Table 2 to obtain a concentration gradient.
[0176] [Table 2]
[0177] Time since sample injection (minutes) Mobile phase A (%) Mobile phase B (%) 0-40.0 95→40 5→60 40.0-40.5 40→5 60→95 40.5-45.0 5 95 45.0-45.5 5→95 95→5 45.5-55.5 95 5
[0178] Flow rate: 0.3mL / min
[0179] Injection volume: 5μL
[0180] ·Testing order and number of sample solutions:
[0181] [Table 3]
[0182] Determination order Sample solution Number of measurements, etc. 1 Blank solution (dissolving solution B) 1 time 2 Standard solution 3 Second time: Standard curve preparation 3 Standard solution 2 Second time: Standard curve preparation 4 Standard solution 1 Second time: Standard curve preparation 5 Blank solution (dissolving solution B) 1 time 6 Sample solution E or sample solution F 1 time
[0183] (Calculation formula)
[0184] Sample solution E (when the measurement object is the water layer):
[0185] Concentration of compound 1 in sample solution E (μg / mL) = (AT-b) / a
[0186] Compound 1 content in AFDX0250 (ppm) = Compound 1 concentration in sample solution E (μg / mL) / MT×P / 100×25000
[0187] AT: Peak area of compound 1 obtained from sample solution E
[0188] b: intercept of the standard curve
[0189] a: slope of the standard curve
[0190] MT: sample weight (mg)
[0191] P: AFDX0250 content (%) of the water layer obtained by the measurement method (1) above
[0192] Sample solution F (when the measurement object is a crystal):
[0193] Concentration of compound 1 in sample solution F (μg / mL) = (AT-b) / a
[0194] Compound 1 content in AFDX0250 (ppm) = Compound 1 concentration in sample solution F (μg / mL) / MT × 25000
[0195] AT: Peak area of compound 1 obtained from sample solution F
[0196] b: intercept of the standard curve
[0197] a: slope of the standard curve
[0198] MT: sample weight (mg)
[0199] The high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine of the present invention The purity of the 6-ketone is as high as 95% or more, and the impurity content is lower than that of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine prepared by a conventional method. Since there is less -6-ketone, it can be expected to be a safer drug.
[0200] The present invention also provides a pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, and is substantially free of impurities.
[0201] The pharmaceutical composition of the present invention comprises (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine having a purity of 95% or more, preferably 97% or more, more preferably 99% or more, and most preferably 99.5% or more. -6-ketone or a salt thereof.
[0202] The pharmaceutical composition of the present invention preferably contains substantially no 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, and more preferably substantially free of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt, particularly preferably substantially free of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone, and 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine It should be noted that 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Keto is a compound represented by the following structural formula.
[0203] [Chemical formula 2]
[0204]
[0205] In the present invention, the term “substantially free” means that 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine is completely free of -6-ketone and other impurities; the presence of impurities cannot be detected by methods commonly used in pharmaceutical analysis such as liquid column chromatography using a chiral column (detector: ultraviolet spectrophotometer); or the impurities are contained in an amount to the extent that their effects and side effects do not occur. For example, the content of impurities in the pharmaceutical composition is relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of α-6-ketone or its salt is less than 5%, preferably less than 3%, more preferably less than 1%, and most preferably less than 0.5%.
[0206] In the present invention, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the pharmaceutical composition The content of -6-ketone or its salt relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For example, the content of 1-6-ketone or its salt is less than 1000 ppm, preferably less than 700 ppm, more preferably less than 500 ppm, further preferably less than 300 ppm, further preferably less than 100 ppm, particularly preferably less than 10 ppm, and most preferably less than 2 ppm.
[0207] In the present invention, 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the pharmaceutical composition The content of -6-ketone or its salt relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For example, the content of 1-6-ketone or its salt is less than 1000 ppm, preferably less than 800 ppm, more preferably less than 600 ppm, and most preferably less than 500 ppm.
[0208] In the present invention, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine in the pharmaceutical composition -6-Keto and 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The total amount of -6-ketone relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For example, the content of 1-6-ketone or its salt is less than 2000 ppm, preferably less than 1000 ppm, more preferably less than 700 ppm, and most preferably less than 500 ppm.
[0209] Unless otherwise specified, the pharmaceutical composition of the present invention may contain, in addition to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt, but in one embodiment, it does not contain (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A pharmaceutically acceptable active ingredient other than -6-ketone or a salt thereof.
[0210] The pharmaceutical composition of the present invention may contain additives as necessary, and examples of the additives include surfactants, isotonic agents, stabilizers, preservatives, antioxidants, high molecular weight polymers, pH adjusters, and bases.
[0211] The pharmaceutical composition of the present invention is preferably an aqueous pharmaceutical composition, but may also be a non-aqueous pharmaceutical composition.
[0212] The pharmaceutical composition of the present invention can be administered orally or parenterally. Examples of administration routes include oral administration, intravenous administration, transdermal administration, topical administration to the eye (e.g., administration by eye drops, administration by eye ointment, administration in the conjunctival sac, administration in the vitreous body, administration under the conjunctiva, administration under the Tenon's capsule, insertion into the conjunctival sac, and application to the eyelid).
[0213] The dosage form of the pharmaceutical composition of the present invention is not particularly limited as long as it can be used as a pharmaceutical product, and examples thereof include eye drops, eye gels, injections, etc. The pharmaceutical composition of the present invention is particularly preferably eye drops. In addition, when the pharmaceutical composition of the present invention is used as a non-aqueous pharmaceutical composition, it can also be formulated into a non-aqueous preparation.
[0214] These can be produced according to a common method in this technical field.
[0215] When the pharmaceutical composition of the present invention is prepared as eye drops, the active ingredient is added to a medium such as purified water or a buffer solution, stirred, and then the pH is adjusted with a pH adjuster to prepare the desired eye drops.
[0216] In addition, additives commonly used in eye drops may be used as necessary. Examples of additives include isotonicity agents, buffers, surfactants, stabilizers, preservatives, solubilizers, and the like.
[0217] When preparing oral preparations such as tablets, capsules, granules, and powders, bulking agents, lubricants, binders, disintegrants, coating agents, and film agents may be added as needed. Examples of bulking agents include lactose, crystalline cellulose, starch, and vegetable oils, examples of lubricants include magnesium stearate and talc, examples of binders include hydroxypropyl cellulose and polyvinyl pyrrolidone, examples of disintegrants include carboxymethyl cellulose calcium and low-substituted hydroxypropyl methylcellulose, examples of coating agents include hydroxypropyl methylcellulose, Macrogol (polyethylene glycol), and silicone resins, and examples of film agents include gelatin film.
[0218] The dosage of the pharmaceutical composition of the present invention can be appropriately changed according to the dosage form, the patient's symptoms, age, weight, age of onset, the doctor's judgment, etc. For example, when the pharmaceutical composition of the present invention is applied locally to the eye as an eye drop, as long as the desired drug effect is sufficiently exerted, the dosage is not particularly limited, and the eye drops can be applied once to several times a day (for example, once to four times, once to six times, once to eight times), and the amount per time is 1 drop to several drops. In addition, it can also be used when wearing contact lenses.
[0219] The pharmaceutical composition of the present invention can be used for the treatment of ophthalmic diseases such as glaucoma, ocular hypertension, myopia, etc.
[0220] Example
[0221] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
[0222] In the following Examples, unless otherwise specified, HPLC (UHPLC) analysis and LC / MS analysis were carried out under the following conditions.
[0223] (HPLC (UHPLC) analysis conditions)
[0224] Detector: UV spectrophotometer (measurement wavelength 210nm)
[0225] Chromatographic column: AQUITY UPLC HS S T3 (inner diameter 2.1 mm, length 100 mm, particle size 1.8 μm; Waters)
[0226] Ghost Peak Capture Column: Ghost Peak Capture Column DS-HP (P / N: 228-59931-91) (Shimadzu Corporation) or columns with equivalent performance quality (In order to remove impurities in the mobile phase, the ghost peak capture column is connected to the back of the mobile phase mixer.)
[0227] Column temperature: around 40°C
[0228] Sample cooler temperature: around 10°C
[0229] Mobile phase A: 0.1 mol / L sodium perchlorate solution (pH 3.0)
[0230] Mobile phase B: acetonitrile
[0231] · Mobile phase delivery: The mixing ratio of mobile phase A and mobile phase B was controlled as shown in Table 4 to obtain a concentration gradient.
[0232] [Table 4]
[0233] Time since sample injection (minutes) Mobile phase A (%) Mobile phase B (%) 0.00—1 6.00 95→40 5→60 1 6.00-20.00 40 60 20.00-20.10 40→95 60→5 20.10-24.00 95 5
[0234] Flow rate: 0.5mL / min
[0235] Injection volume: 2μL
[0236] Area measurement range: from the peak of the solvent to 20 minutes after injection
[0237] (LC / MS analysis conditions)
[0238] Detector: Mass spectrometer
[0239] Monitored ions: m / z 288 (ESI, Positive)
[0240] ·Chromatographic column: X Bridge C18 (inner diameter 2.1 mm, length 150 mm, particle size 3.5 μm; Waters)
[0241] Column temperature: around 40°C
[0242] Sample cooler temperature: Let the temperature be what it is
[0243] Mobile phase C: 10 mM ammonium acetate solution
[0244] Mobile phase B: acetonitrile
[0245] · Mobile phase delivery: The mixing ratio of mobile phase C and mobile phase B was controlled as shown in Table 5 to obtain a concentration gradient.
[0246] [Table 5]
[0247] Time since sample injection (minutes) Mobile phase A (%) Mobile phase B (%) 0-40.0 95→40 5→60 40.0-40.5 40→5 60→95 40.5-45.0 5 95 45.0-45.5 5→95 95→5 45.5-55.5 95 5
[0248] Flow rate: 0.3mL / min
[0249] Injection volume: 5μL
[0250] ·Testing order and number of sample solutions:
[0251] [Table 6]
[0252]
[0253] Example 1: Preparation of AFDX0250 (1)
[0254] [Chemical formula 3]
[0255]
[0256] (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine was prepared according to the following steps. -6-Keto (AFDX0250).
[0257] Process 1
[0258] Under nitrogen atmosphere, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine was added at room temperature. To a solution of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine (AFDX0250, Compound 1) (200 g, 0.695 mol) in acetonitrile (3200 g) were added (R)-2-(diethylamino)methylpiperidine dihydrochloride (hereinafter, sometimes referred to as "Compound 2"; 178 g, 0.732 mol), sodium iodide (26.0 g, 0.174 mol) and sodium bicarbonate (184 g, 2.19 mol), and the mixture was heated at an internal temperature of 73.0 to 74.5°C. The reaction solution at each time point (after 2 hours, 3 hours, 4 hours and 5 hours of reaction) was subjected to ultra-high performance liquid chromatography (UHPLC), and the area percentage of AFDX0250, Compound 1 and 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine was determined. -6-ketone (hereinafter, sometimes referred to as "compound 3") was quantified.
[0259] Process 2
[0260] After the reaction was allowed to proceed for 5 hours in step 1, the reaction solution was cooled and concentrated to obtain a crude product AFDX0250 (1231.56 g). Water (1800 g) was added, and concentrated hydrochloric acid (155 mL) was added dropwise at an internal temperature of 4.0 to 5.5°C until the pH became below 1 (pH 0.8), and then ethyl acetate (1800 g) was used for three liquid separations. The water layer of each liquid separation was measured by liquid chromatography (UHPLC), and AFDX0250 and compound 3 were quantified by the area percentage method. In addition, the content of compound 1 was measured by liquid chromatography mass spectrometry (LC / MS).
[0261] Process 3
[0262] To the aqueous layer obtained in step 2, water (1400 g) and acetonitrile (780 g) were added, and the mixture was stirred at an internal temperature of 2.0 to 5.0°C. Subsequently, a 3.25 N potassium hydroxide aqueous solution was added dropwise until the pH became below 11, and the mixture was stirred for 5 hours. The precipitated solid was filtered under reduced pressure, and the filtrate was washed with water (2000 g), and then dried under reduced pressure at 50°C to obtain crude AFDX0250 (274.35 g, yield 93.3%) as a light brown solid. The obtained light brown solid was measured by liquid chromatography (UHPLC), and AFDX0250 and compound 3 were quantified by the area percentage method. In addition, the content of compound 1 was measured by liquid chromatography mass spectrometry (LC / MS).
[0263] It should be noted that the contents of AFDX0250 and compound 3 in the reaction solution obtained in step 1, the aqueous layer obtained in step 2 and the solid obtained in step 3, and the content of compound 1 in the reaction solution obtained in step 1 were measured according to the method for measuring the content of AFDX0250 or a salt thereof (1) in the present specification.
[0264] The content of Compound 1 contained in AFDX0250 in the aqueous layer obtained in Step 2 and the solid obtained in Step 3 was measured according to the method for measuring the content of Compound 1 (2) in the present specification.
[0265] The results of UHPLC analysis and LC / MS analysis of the reaction solution and sample solution in each step are shown in Table 7. Table 7 shows the contents of AFDX0250, Compound 1, and Compound 3. In addition, a) in the table represents the content of Compound 1 measured by liquid chromatography-mass spectrometry.
[0266] [Table 7]
[0267]
[0268] This experiment shows that the production method of the present invention can remove compound 1, which is positive in the Ames test, to an undetectable level, and can obtain AFDX0250 with high yield and high purity. Therefore, the production method of the present invention can produce AFDX0250 with high yield and high purity.
[0269] Furthermore, it was shown that AFDX0250 can be produced even when triethylamine is used instead of sodium bicarbonate in the above-mentioned step 1.
[0270] Example 2: Quantitative analysis of AFDX0250 produced by the production method of the present invention and a known production method
[0271] AFDX0250 produced by the production method of the present invention (using 20 mL of acetonitrile per 1 g of compound 1 as a reaction solvent) and a known production method (using 10 mL of acetonitrile per 1 g of compound 1 as a reaction solvent) were quantitatively analyzed, and the area % of AFDX0250 and impurities were compared.
[0272] Specifically, the batch amount of compound 1 was changed from 200 g to 95 g, and the amount of compound 2 and the reagent (equivalent to 1 amount of compound 1) was prepared in the same manner as in Example 1 to produce AFDX0250 (Example 2). In addition, AFDX0250 (Comparative Example 1) was prepared in the same manner as in Example 2, except that 10 mL of acetonitrile was used instead of 20 mL of acetonitrile relative to 1 g of compound 1. The obtained reaction solution was used to prepare a test solution in the same manner as in Example 1. Each test solution was analyzed by UHPLC.
[0273] Table 8 shows the results of UHPLC analysis of AFDX0250 obtained by the production method of the present invention (Example 2) and a known production method (Comparative Example 1).
[0274] [Table 8]
[0275]
[0276] This experiment shows that the production method of the present invention can significantly remove impurities including compound 1. Therefore, it is shown that the production method of the present invention improves the purity of AFDX0250.
[0277] Example 3: Preparation of AFDX0250 (2)
[0278] [Chemical formula 4]
[0279]
[0280] Under nitrogen atmosphere, 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine was added at room temperature. Compound 2 (135 g, 5.53 mol) and sodium bicarbonate (140 g, 16.6 mol) were added to an acetonitrile solution (40.0 mL) of -6-ketone (hereinafter, sometimes referred to as "Compound 4") (2.00 g, 5.27 mol), and the mixture was heated at an internal temperature of 73.0°C for 23 hours. The reaction solution was filtered under reduced pressure, and the filtrate was rinsed 5 times with acetonitrile (2.0 mL). The filtrate was concentrated to dryness, and acetonitrile (7.60 mL) and water (9.20 mL) were added to the residue, stirred and dissolved, and cooled to 0°C. 3.25N potassium hydroxide was added to the solution until the pH reached 11.2 to 11.4, and stirred at 0°C for 3 hours. The precipitated solid was filtered under reduced pressure and rinsed with water (13.2 mL) to obtain a wet solid. It was dried under reduced pressure at 50°C to obtain AFDX0250 (1.04 g, yield 46.9%) as a light brown solid.
[0281] AFDX0250 1 H-NMR data are as follows.
[0282] 1 H-NMR (400 MHz, CDCl 3 )δ0.83-0.97(m, 6H), 1.07-1.80(m, 6H), 1.95-2.63(m, 7.5H), 2.72-2.82(m, 0.5H), 3.07-3.27(m, 0.5H), 3.68(s, 1H), 4.10-4.28(m , 0.5H), 7.27-7.33 (m, 1H), 7.36-7.48 (m, 1H), 7.55-7.70 (m, 3H), 7.93 (d, J=7.8Hz, 1H), 8.30 (d, J=2.5Hz, 1H), 9.90-10.30 (br, 1H).
[0283] This experiment shows that when 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine When -6-ketone is reacted with (R)-2-(diethylamino)methylpiperidine dihydrochloride, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can also be produced. -6-Keto.
[0284] Example 4: Purification of AFDX0250 (1)
[0285] [Chemical formula 5]
[0286]
[0287] Under nitrogen atmosphere, a solution of crude AFDX0250 (250 g, 0.593 mol) obtained in Example 1 in 1-propanol (800 g) was heated and stirred at an internal temperature of 89.7 to 90.1°C for 3 hours, then cooled to an internal temperature of 50.1°C at a cooling rate of 0.5°C / min, and water (1500 g) was added at an internal temperature of 48.1 to 50.9°C over 30 minutes, followed by stirring at 50.3 to 50.9°C for 30 minutes. Then, the solution was cooled to an internal temperature of 6.3°C at a cooling rate of 0.5°C / min, and stirred at an internal temperature of 0.8 to 6.3°C for 17 hours. The precipitated solid was filtered under reduced pressure, and the filtrate was washed with water (2500 g), and dried under reduced pressure at 50°C to obtain purified crude AFDX0250 (217.09 g, yield 86.8%) as a light brown solid. The obtained light brown solid was subjected to ultra-high performance liquid chromatography (UHPLC), and AFDX0250, compound 1, compound 3, and a compound with a relative retention time of 1.06 (hereinafter, sometimes referred to as "compound 5") were quantitatively determined by the area percentage method. In addition, the content of compound 1 was measured by liquid chromatography-mass spectrometry (LC / MS).
[0288] The results of UHPLC analysis and LC / MS analysis are shown in Table 9. In addition, a) in the table represents the content of compound 1 measured by liquid chromatography-mass spectrometry.
[0289] [Table 9]
[0290] Measurement object AFDX0250 Compound 1 Compound 3 Compound 5 Coarse AFDX0250 98.43% <![CDATA[3.1ppm a) ]]> 0.44% 0.44% Purified crude AFDX0250 99.47% <![CDATA[1.1ppm a) ]]> 0.03% 0.22%
[0291] This experiment shows that according to the purification method of the present invention, AFDX0250 can be obtained with a high yield, and in addition to reducing compound 1 and compound 3, compound 5 as an impurity can be further reduced. Therefore, by using the purification method of the present invention, AFDX0250 with a higher yield and high purity can be produced.
[0292] Example 5: Purification of AFDX0250 (2)
[0293] [Chemical formula 6]
[0294]
[0295] In order to achieve appropriate properties and ensure the quality of pharmaceuticals, the color, which is one of the items showing the properties of the original drug, needs to be controlled in the production process of the original drug. Therefore, crude AFDX0250 is dissolved in an organic solvent by heating, activated carbon is added and stirred, and the activated carbon is removed by filtration to decolorize and remove the coloring components to purify AFDX0250.
[0296] In this test, each sample using Egret A (0.05w / w, 0.10w / w and 0.15w / w) and Egret P (0.10w / w and 0.15w / w) as activated carbon, and using ethanol (EtOH), 1-propanol (1-PrOH) and N-methylpyrrolidone (NMP) as organic solvent was prepared. It should be noted that, with respect to the sample containing NMP as a solvent, the sample using Egret A (0.15w / w) and Egret P (0.10w / w and 0.15w / w) was not prepared.
[0297] The amount of ethanol and 1-propanol added was 20 mL each per 1 g of crude AFDX0250, and the stirring temperature was 70° C. The amount of NMP added was 2.5 mL per 1 g of crude AFDX0250, and the stirring temperature was 70° C.
[0298] In order to confirm whether the coloring components were removed, the properties of the samples containing ethanol, 1-propanol and NMP were confirmed before and after the activated carbon treatment. In addition, HPLC analysis was performed for each sample at each time point (before the addition of activated carbon, 1 hour after the addition of activated carbon, and 3 hours after the addition of activated carbon).
[0299] The properties of each sample (powder and DMSO solution) before and after activated carbon treatment are shown in Figure 1 For the powder, each sample containing each organic solvent was filtered under reduced pressure, the filtrate was concentrated under reduced pressure, and the obtained wet solid was dried under reduced pressure at 50°C to confirm its properties. In addition, for the DMSO solution, the obtained solid was dissolved in 10% dimethyl sulfoxide (DMSO) to prepare a solution, and its properties were confirmed.
[0300] Tables 10 to 12 show the results of HPLC analysis of a sample containing ethanol (EtOH), a sample containing 1-propanol (1-PrOH), and a sample containing NMP.
[0301] [Table 10]
[0302] Samples containing ethanol
[0303]
[0304] [Table 11]
[0305] Samples containing 1-propanol
[0306]
[0307] [Table 12]
[0308] Samples containing NMP
[0309]
[0310] This experiment showed that the coloring component and Compound 3 as an impurity can be sufficiently removed by performing the activated carbon treatment using an alcohol solvent.
[0311] Example 6: Purification of AFDX0250 (3)
[0312] Under nitrogen atmosphere, Egret A (30.0 g) as activated carbon was added to a solution of crude AFDX0250 (200 g, 0.474 mol) purified in Example 4 in ethanol (3200 g) at room temperature, and heated and stirred at an internal temperature of 69.0 to 72.4° C. for 1 hour, and then filtered under reduced pressure using a filtration device filled with a filter aid, and washed with ethanol (320 g) preheated to 70° C. The filtrate was concentrated under reduced pressure to obtain a concentrated residue (989.04 g).
[0313] In the present test, in order to carry out the recrystallization step continuously with the activated carbon treatment step from the viewpoint of the work efficiency of the purification step, the alcohol used in the activated carbon treatment was combined with a poor solvent to carry out the recrystallization step.
[0314] Using ethanol or 1-propanol as an alcohol solvent, and using acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK) or n-heptane as a ketone solvent as a poor solvent, for their combination, the recrystallization process is carried out as follows with the respective total solvent amounts of 10 v / w (ratio 1:3) and 20 v / w (ratio 1:1).
[0315] The alcohol solution of AFDX0250 was heated and stirred at 50°C for 0.5 to 1 hour. After adding each poor solvent to the solution, it was further heated and stirred for 1 hour. Then, it was cooled to 5°C and aged for 24 hours. The suspended solution was filtered and the filtrate was dried under reduced pressure at 90°C. The properties of the obtained dried product were confirmed and analyzed by HPLC. In addition, the dried product was made into a 10% dimethyl sulfoxide (DMSO) solution and its properties were confirmed.
[0316] The properties of the dried products and DMSO solutions obtained in the recrystallization step using ethanol and 1-propanol as alcoholic solvents, and the properties of the dried products and DMSO solutions before purification are shown in FIG. Figure 2 and Figure 3 In addition, the results and yields of HPLC analysis of each dry product obtained in the recrystallization step using ethanol and 1-propanol as an alcoholic solvent and the dry product before purification are shown in Tables 13 and 14, respectively.
[0317] [Table 13]
[0318] Alcohol solvent: ethanol
[0319]
[0320] [Table 14]
[0321] Alcohol solvent: 1-propanol
[0322]
[0323] This experiment showed that by using a mixed solvent of an alcohol solvent and a ketone solvent for the recrystallization step, the coloring component and Compound 1 as an impurity can be sufficiently removed, thereby improving the purity of AFDX0250.
[0324] Example 7: Purification of AFDX0250 (4)
[0325] [Chemical formula 7]
[0326]
[0327] Methyl isobutyl ketone (MIBK) (640 g) was added to the ethanol solution of AFDX0250 treated with activated carbon in Example 6, and the mixture was concentrated. 1 H-NMR measurement was used to calculate the mass volume percentage of ethanol and MIBK relative to AFDX0250, and the amount of ethanol was adjusted so that the total amount of ethanol was 2.5 v / w. Next, the reaction mixture was heated to 63-67°C and stirred for 30 minutes. MIBK was added dropwise over 48 minutes so that the total amount was 7.5 v / w, and stirred at 63-67°C for 1 hour. Next, the reaction mixture was cooled to 0-5°C, aged for 24 hours, and filtered to obtain crystals (first recrystallization).
[0328] The obtained AFDX0250 was prepared into a test solution according to the method for measuring the content of AFDX0250 or a salt thereof (1) in the present specification, and the test solution was subjected to HPLC analysis.
[0329] The obtained AFDX0250 was dissolved in ethanol, and the solution was recrystallized for the second time in the same manner as the first recrystallization. The obtained wet solid AFDX0250 was dried under reduced pressure at 90°C for 14 hours and 35 minutes to obtain AFDX0250 (152.27 g, yield 76.1%).
[0330] The obtained AFDX0250 was prepared into a test solution in the same manner as the AFDX0250 obtained in the first recrystallization according to the method for measuring the content of AFDX0250 or a salt thereof (1) in the present specification, and the test solution was subjected to HPLC analysis.
[0331] AFDX0250 1 H-NMR data are as follows.
[0332] 1 H-NMR (400 MHz, CDCl 3 )δ0.85-0.97(m, 6H), 1.08-1.75(m, 6H), 1.96-2.60(m, 7.5H), 2.72-2.82(m, 0.5H), 3.10-3.24(m, 0.5H), 3.68(s, 1H), 4.12-4.26(m , 0.5H), 7.27-7.33 (m, 1H), 7.36-7.43 (m, 1H), 7.59-7.67 (m, 3H), 7.93 (d, J=7.8Hz, 1H), 8.30 (d, J=3.2Hz, 1H), 10.00-11.00 (br, 1H)
[0333] The results of HPLC analysis of AFDX0250 obtained by the first and second recrystallizations are shown in Table 15. In the table, "ND" means "not detected", and a) indicates the content of Compound 1 measured by liquid chromatography-mass spectrometry.
[0334] [Table 15]
[0335]
[0336] This experiment showed that by performing recrystallization after activated carbon treatment, compound 5 can be sufficiently removed as with compound 1. Therefore, it was shown that the purity of AFDX0250 can be further improved by combining activated carbon treatment and recrystallization steps.
[0337] Industrial Applicability
[0338] According to the present invention, compared with the known method, (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine can be produced with high yield and high purity. -6-ketone or its salt. In addition, it can inhibit 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone and other impurities.
[0339] In addition, according to the present invention, it is possible to provide a high-purity (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt, and (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine containing high purity A pharmaceutical composition of -6-ketone or a salt thereof.
Claims
1. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt production method, comprising the step of: 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine a step of reacting (R)-2-(diethylamino)methylpiperidine or a salt thereof with (R)-2-(diethylamino)methylpiperidine or a salt thereof in an organic solvent in the presence of an alkali metal iodide under alkaline conditions, The organic solvent contains 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For -6-ketone or its salt, 15 to 50 mL of acetonitrile.
2. The manufacturing method according to claim 1, wherein: The organic solvent is 1g of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For -6-ketone or its salt, 15 to 50 mL of acetonitrile.
3. The production method according to claim 1 or 2, further comprising the step of adding water and an acid to the reaction mixture to adjust the pH, followed by extraction with an organic solvent.
4. The manufacturing method according to claim 3, wherein: The extraction with the organic solvent was performed two or more times.
5. The manufacturing method according to claim 3 or 4, wherein: The organic solvent was ethyl acetate.
6. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or its salt production method, comprising the step of: 11-(2-iodoacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of reacting -6-ketone or a salt thereof with (R)-2-(diethylamino)methylpiperidine or a salt thereof in an organic solvent under alkaline conditions.
7. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of crystallizing the -6-ketone or its salt in a mixed solution of 1-propanol and water.
8. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of treating -6-ketone or its salt with activated carbon in an alcohol solvent.
9. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A method for purifying -6-ketone or a salt thereof, comprising: (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine A step of recrystallizing -6-ketone or a salt thereof in a mixed solution of an alcoholic solvent and a ketone solvent.
10. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, the purity of which is 95% or more.
11. (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, wherein The content of impurities is less than 5%.
12. A pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, derived from (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of impurities in (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of α-6-ketone or its salt is less than 5%.
13. The pharmaceutical composition according to claim 12, wherein The content of impurities is less than 1%.
14. A pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof, and substantially free of 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-Keto.
15. The pharmaceutical composition according to claim 14, wherein 11-(2-Chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of -6-ketone relative to (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine For 1-6-ketone or its salt, the concentration is less than 1000 ppm.
16. The pharmaceutical composition according to claim 14 or 15, which is substantially free of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-ketone or a salt thereof.
17. The pharmaceutical composition according to claim 16, wherein 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine The content of -6-ketone or its salt is less than 1000 ppm.
